Toho Holdings Co., Ltd. Share Price

Equities

8129

JP3602600003

Pharmaceuticals

Delayed Japan Exchange 08:00:00 20/06/2024 am IST 5-day change 1st Jan Change
3,716 JPY -0.83% Intraday chart for Toho Holdings Co., Ltd. -3.30% +15.33%

Financials

Sales 2024 1,477B 9.34B 779B Sales 2025 * 1,447B 9.15B 764B Capitalization 235B 1.49B 124B
Net income 2024 20.66B 131M 10.9B Net income 2025 * 12.26B 77.57M 6.47B EV / Sales 2024 0.15 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.16 x
P/E ratio 2024
11.4 x
P/E ratio 2025 *
19.3 x
Employees 7,699
Yield 2024
1.1%
Yield 2025 *
1.4%
Free-Float 67.82%
More Fundamentals * Assessed data
Dynamic Chart
Jefferies Adjusts Toho Holdings' Price Target to 4,400 Yen From 3,800 Yen, Keeps at Buy MT
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd.'s Equity Buyback announced on September 15, 2023, has closed with 1,838,800 shares, representing 2.87% for ¥5,999.94 million. CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 2024 CI
Toho Holdings Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31, 2024, Payable on December 1, 2023, Provides Dividend Guidance for the Year Ending 2024 CI
MICIN, Inc. announced that it has received ¥4 billion in funding from MTG Ventures Co., Ltd., Alfresa Corporation, Toho Holdings Co., Ltd. and other investors CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Toho Holdings Co., Ltd. announces an Equity Buyback for 2,500,000 shares, representing 3.87% for ¥6,000 million. CI
Toho Holdings Co., Ltd. authorizes a Buyback Plan. CI
United Immunity, Co., Ltd. announced that it has received ¥800 million in funding from Toho Holdings Co., Ltd., The University of Tokyo Edge Capital Partners Co., Ltd., Saisei Ventures LLC, Venture Labo Investment CI
Toho Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 2023 and Fiscal Year Ending March 31, 2024 CI
Toho Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Year Ending March 31, 2024 CI
Tranche Update on Toho Holdings Co., Ltd.'s Equity Buyback Plan announced on May 31, 2023. CI
Toho Holdings Co., Ltd.'s Equity Buyback announced on May 31, 2023, has closed with 2,360,300 shares, representing 3.52% for ¥5,999.88 million. CI
More news
1 day-0.83%
1 week-3.30%
Current month-6.42%
1 month-0.46%
3 months+7.18%
6 months+13.99%
Current year+15.33%
More quotes
1 week
3 691.00
Extreme 3691
3 850.00
1 month
3 691.00
Extreme 3691
4 077.00
Current year
3 121.00
Extreme 3121
4 220.00
1 year
2 583.50
Extreme 2583.5
4 220.00
3 years
1 678.00
Extreme 1678
4 220.00
5 years
1 653.00
Extreme 1653
4 220.00
10 years
1 386.00
Extreme 1386
4 220.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 01/87/01
Director of Finance/CFO 72 01/12/01
Director/Board Member 63 01/15/01
Members of the board TitleAgeSince
Director/Board Member 84 01/66/01
Director of Finance/CFO 72 01/12/01
Director/Board Member 74 01/14/01
More insiders
Date Price Change Volume
20/24/20 3,716 -0.83% 107 600
19/24/19 3,747 -0.79% 229,000
18/24/18 3,777 -1.69% 215,200
17/24/17 3,842 +0.10% 227,900
14/24/14 3,838 -0.13% 235,100

Delayed Quote Japan Exchange, June 20, 2024 at 08:00 am IST

More quotes
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3,747 JPY
Average target price
3,735 JPY
Spread / Average Target
-0.32%
Consensus